Lovely few days in Germany at the @EACRnews Goodbye Flat Biology Ex Vivo to In Vivo Models of Cancer conference! 🧫#eacr #oncology

A landmark moment for pancreatic cancer, these findings highlight what transformative progress can look like. Congratulations to @EileenMOReilly & team @MSKCancerCenter advancing this research driving forward a new standard of care in a disease that has long needed breakthroughs

We’re delighted to see @CancerInstIRE Research Director, Prof Lorraine O’Driscoll as she opens the #Cancerconference, setting the stage for a powerful programme focused on innovation, collaboration and impact in cancer research and care #CancerResearch

We are delighted to see Prof John O’Leary, one of the chairs of the Cancer Screening & Prevention section, welcoming everyone at the cancer conference today, offering thoughtful, compelling insights on prevention, leadership and impact across cancer care. #CancerPrevention

This isn’t a random scientist who got lucky. Mariano Barbacid discovered the first human oncogene in 1982. He isolated H-RAS from bladder cancer cells and proved a single point mutation could trigger cancer. That finding launched the entire field of molecular oncology. KRAS mutations cause 90% of pancreatic cancers. For 43 years, oncologists called KRAS “undruggable” because the protein had no obvious binding pocket. Barbacid spent the last decade using genetically engineered mice to systematically test every node in the KRAS signaling pathway, looking for combinations that would work without killing the patient. The triple therapy blocks KRAS three ways at once: the main growth signal, the escape routes through EGFR and HER2, and the stress-response backup through STAT3. Cut the engine, seal the exits, disable the emergency system. Tumors vanished in mice and didn’t return for 200 days after treatment stopped. Pancreatic cancer has a 13% five-year survival rate. 8% for the ductal adenocarcinoma type this therapy targets. Most patients live one year after diagnosis. The catch: this is preclinical. Human trials are 3 years away. One of the drugs, RMC-6236, might get approved this year, but the full triple combination has regulatory hurdles. Still. The man who discovered human oncogenes in 1982 may have just figured out how to eliminate the cancer those genes cause. That’s a 43-year arc from first principles to potential cure. Science rarely works this clean.

🇪🇸 A research team led by Spanish oncologist Mariano Barbacid has successfully eradicated pancreatic cancer in mice for the first time, offering hope for a human cure. The experiment involved treating the mice by combining three low-toxicity drugs, according to a study published today. Dr. Barbacid has made a number of high profile discoveries in medical science, with his National Cancer Research Centre in Spain becoming one of the world's leading centres of cancer research. Pancreatic cancer is one of the most aggressive cancers, with the variant treated having a five-year survival rate of less than 5%. Clinical trials will begin soon, followed by approval for use of this treatment in humans. Follow: @europa

A team of scientists from the Spanish Cancer Research Centre, led by the renowned Dr Mariano Barbacid, has achieved the complete and permanent disappearance of pancreatic cancer in experimental models. This discovery could make a difference in the fight against this disease. 👏

Young Scientist: Winner scoops prize for brain cancer diagnostic tool irishtimes.com/science/2026/…

The @BreakthroCancer Cancer Revolution exhibition has been extended! 👏🏼 A fantastic opportunity for anyone who hasn’t had the chance to attend so far! 👩🏼‍🔬🧫🔬#CancerRevolution #MakeMoreSurvivors breakthroughcancerresearch.i…

🎤 We’re so moved by the incredible feedback on our Cancer Revolution exhibition. Visitors said they left feeling hopeful, inspired by survivor stories & the progress of cancer research in Ireland.💙 Their words capture its essence: real progress and real hope. #MakeMoreSurvivors

Cancer clinical trials save lives, offering potential life-saving treatments to patients. In Ireland, access to these trials are limited and requires increased investment by the Irish government. Everyone, regardless of age or location, deserves the best possible outcomes.

Congratulations to Professor Derek Doherty on his retirement from @TCDTMI @tcddublin A mentor, supervisor, leader, colleague & friend to many. Enjoy this next chapter, Derek! #Immunology #IrishResearch

Thanks to @IASLC for the opportunity to present our #translational research study on #FGFR2 in #NSCLC at the #WCLC2025 in #Barcelona This work undertaken by #MedicalScientist Conor Murtagh @stjamesdublin under the my co-supervision with @finnstev @CancerInstIRE @TrinityMed1 #LCSM

🌟AllCaN Oesophageal is excited to announce that registration for the AllCaN Oesophageal Symposium 2025 is now open! 🌟 Registration closes on 30th September at 5:00 PM. 🚨 View the symposium programme and register here: allcan.ie/symposium-2025/.

Latest work on our in vitro alternative liver models just out! 🧫 @TrinityMed1 @prinamea @LBCAM_TCD sciencedirect.com/science/ar…

Big News!📰 @CancerInstIRE is now officially Ireland’s first Comprehensive Cancer Centre,@OECI_EEIG🧬 This means better care, cutting-edge treatment & more support for patients. A very proud moment for Irish Healthcare! 🏥

A momentous day for @CancerInstIRE @stjamesdublin @tcddublin on the launch of its designation as the first @OECI_EEIG Comprehensive #Cancer Centre in #Ireland

Huge congratulations Dr Matt!!! @maitiuomurchu !!!!! 🎉🎉🎉👏🏼👏🏼👏🏼

PhD student, @Lorrainesmith_1 is exploring a new way to treat Barrett’s oesophagus using electroporation - a gentler method. Funded by @BreakthroCancer through the @AllCaN_BCR programme, her work could pave the way for a new clinical trial for people with #BarrettsOesophagus